NICE Appraisals for Rucaparib and Niraparib - patient experts needed

[OvacomeSupport]

Dear All

NICE will be appraising these 2 PARP inhibitors at the end of the year for approval for NHS availability and they have asked for nominated patient experts. The names of the appraisals are:

Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy

and

Rucaparib for treating relapsed ovarian, fallopian tube or peritoneal cancer

that has a BRCA mutation

A patient expert would need to be willing to submit a personal statement about their experience and to attend the NICE committee meeting in London on Tuesday 5 December 2017.

If you have been treated with either of these drugs and think you might like to contribute to the NICE appraisal process please let me know by emailing me [e-mail] and I will contact you to discuss the process in more detail.

I'm away on leave next week (24-28 July 2017) but if you send me an email I will get in contact the following week.

Best wishes

Anna

Support Service Manager

[Hilsuk]

Hi Anna , I would be interested in helping with the rucaparib meeting assuming it didnt clash with the nirapabib meeting which I am already attending as a patient expert . What is your email address please ? Thanks Hilary

[TheOvacomeTeam Partner in reply to Hilsuk]

Hello Hilsuk,

You can email Anna on [e-mail]

Best wishes,

The Ovacome Team.